Sakaguchi Koichi, Mizuta Naruhiko, Imai Aya, Nakatsukasa Katsuhiko, Morita Midori, Soushi Mari, Taguchi Tetsuya
Dept. of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Japan.
Gan To Kagaku Ryoho. 2012 Jul;39(7):1081-5.
Nab-paclitaxel was administered to 9 patients with refractory advanced or recurrent breast cancer from 1 to 8 times(median 4)triweekly. The median cumulative dose was 775mg/m2(range 260-2, 000), and the median delivered dose intensity was 66. 7mg/m2/week(range 58. 3-86. 7). The response to treatment was CR in one patient, PR in 2 patients, SD in one patient, and PD in 4 patients. In one patient, treatment had to be suspended because of grade 3 peripheral neuropathy. The clinical benefit was 33%. All 4 PD patients were administered other salvage treatments and are alive. Adverse events included 6 case of neutropenia(grade 3-4 in 4 cases), grade 3 AST/ALT elevations in one patient, grade 3 myalgia in one patient. No case of febrile neutropenia was seen. All reactions were under control except for one patient with grade 3 peripheral neuropathy. Concurrent trastuzumab administration was safe also. In conclusion, nab-paclitaxel could be administered safely, and may contribute to the treatment of refractory advanced or recurrent breast cancer.
对9例难治性晚期或复发性乳腺癌患者每3周1次给予纳米白蛋白结合型紫杉醇，共给药1至8次（中位数为4次）。累积剂量中位数为775mg/m²（范围260 - 2000），给药剂量强度中位数为66.7mg/m²/周（范围58.3 - 86.7）。治疗反应为1例完全缓解（CR），2例部分缓解（PR），1例疾病稳定（SD），4例疾病进展（PD）。1例患者因3级周围神经病变不得不暂停治疗。临床获益率为33%。所有4例疾病进展患者均接受了其他挽救治疗，目前仍存活。不良事件包括6例中性粒细胞减少（4例为3 - 4级），1例患者出现3级谷草转氨酶/谷丙转氨酶升高，1例患者出现3级肌痛。未观察到发热性中性粒细胞减少病例。除1例3级周围神经病变患者外，所有反应均得到控制。同时给予曲妥珠单抗也是安全的。总之，纳米白蛋白结合型紫杉醇给药安全，可能有助于难治性晚期或复发性乳腺癌的治疗。
